Comparison of 26G and 30G Needles for Masseter Trigger Point Injections in Patients With Myofascial Pain Syndrome (MASS-NEEDLE)
Comparison of Two Needle Gauges (26G and 30G) for Masseter Muscle Trigger Point Injection in Myofascial Pain Syndrome: A Randomized Split-Face Controlled Trial
This randomized split-face study aims to compare the effects of 26G and 30G needles used for masseter trigger point injections with lidocaine in patients with myofascial pain syndrome. Both needle sizes are routinely used in clinical practice. Pain reduction from baseline to day 14 will be compared between the two sides of the face. Secondary outcomes include pain reduction at day 7, procedural pain, injection-site tenderness at 48 hours, bruising, and patient preference. The split-face design allows both needle sizes to be evaluated in the same patient, minimizing individual differences.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Both 26G and 30G needles were routinely used for masseter trigger point injection in our clinic. Comparing these gauges under otherwise standardized conditions may help clarify whether needle selection affects short-term pain reduction, procedural pain, and patient preference. A randomized split-face design permits this comparison within the same patient, reducing the influence of differences between individuals.
The primary objective of this study was to compare the within-patient reduction in palpation-evoked masseter pain between sides treated with 26G and 30G needles from baseline to day 14 following lidocaine injection. Secondary objectives were to compare pain reduction at day 7, overall procedural pain, injection-site tenderness at 48 hours, ecchymosis, and patient preference.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Ceylan Güzel, Dr
- Número de telefone: +90 5364501650
- E-mail: ceylan.guzel@medipol.edu.tr
Locais de estudo
-
-
-
Istanbul, Turquia (Türkiye), 34214
- Medipol Mega University Hospital
-
Contato:
- Ceylan Güzel, Dr.
- Número de telefone: +905364501650
- E-mail: ceylan.guzel@medipol.edu.tr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Adults aged 18-65 years.
Bilateral masseter myofascial pain persisting for at least 8 weeks.
Baseline palpation-evoked pain score of ≥6 on an 11-point Numerical Rating Scale (NRS) on each side.
Presence of at least one active myofascial trigger point within a palpable taut band in each masseter muscle, reproducing the patient's familiar pain.
Diagnosis established according to the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD).
No previous treatment for masseter myofascial pain.
Exclusion Criteria:
- Concomitant temporomandibular joint arthralgia.
Known allergy to local anesthetics.
Pregnancy or lactation.
Active infection, open lesion, or malignancy at the injection site.
Bleeding diathesis or use of anticoagulant or antiplatelet medications.
Inability to cooperate with study procedures.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Bilateral Masseter Trigger Point Injection 26 G
All participants received bilateral masseter trigger point injections in a single session. A 26-gauge (26G) needle was randomly assigned to one masseter muscle and a 30-gauge (30G) needle to the contralateral masseter muscle using a computer-generated randomization sequence. Each masseter received 0.3 mL of 2% lidocaine without vasoconstrictor using a standardized injection technique. The right masseter was injected first in all participants. Participants and the outcome assessor were blinded to needle-gauge allocation, whereas the injecting clinician was not blinded. |
A 26-gauge (0.45 × 13 mm) needle was used for masseter trigger point injection. A total of 0.3 mL of 2% lidocaine without vasoconstrictor was administered using a standardized injection technique. |
|
Experimental: Bilateral Masseter Trigger Point Injection 30 G
All participants received bilateral masseter trigger point injections in a single session. A 26-gauge (26G) needle was randomly assigned to one masseter muscle and a 30-gauge (30G) needle to the contralateral masseter muscle using a computer-generated randomization sequence. Each masseter received 0.3 mL of 2% lidocaine without vasoconstrictor using a standardized injection technique. The right masseter was injected first in all participants. Participants and the outcome assessor were blinded to needle-gauge allocation, whereas the injecting clinician was not blinded. |
A 30-gauge (0.45 × 13 mm) needle was used for masseter trigger point injection. A total of 0.3 mL of 2% lidocaine without vasoconstrictor was administered using a standardized injection technique. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Between-Needle Difference in Palpation-Evoked Masseter Pain Reduction From Baseline to Day 14
Prazo: Baseline and Day 14 (14 days after injection)
|
Palpation-evoked masseter pain was assessed separately on each side using an 11-point Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst possible pain). At baseline and day 14, pain was recorded at the most painful trigger point identified during each assessment. Pain reduction was calculated as baseline NRS minus day 14 NRS for each side. The primary outcome was the within-participant difference in pain reduction between the 30G and 26G needle interventions (30G minus 26G). Positive values indicated greater pain reduction with 30G. |
Baseline and Day 14 (14 days after injection)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Between-Needle Difference in Palpation-Evoked Masseter Pain Reduction at Day 7
Prazo: Baseline and Day 7
|
Palpation-evoked masseter pain was assessed separately on each side using an 11-point Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst possible pain). Pain reduction was calculated as baseline NRS minus day 7 NRS for each side. The within-participant difference in pain reduction between the 30G and 26G needle interventions was calculated as 30G minus 26G. Positive values indicated greater pain reduction with 30G. |
Baseline and Day 7
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall Procedural Pain During Masseter Trigger Point Injection
Prazo: Day 0 (within 60 seconds after each injection)
|
Overall procedural pain was assessed separately for the 26G and 30G needle interventions using an 11-point Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst possible pain). Participants rated the entire injection procedure, including skin penetration, intramuscular needle manipulation, and lidocaine administration. Pain was recorded within 60 seconds after each injection. Within-participant pain scores were compared between needle gauges. |
Day 0 (within 60 seconds after each injection)
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- E-10840098-50.04-5377
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .